Virtus ETF Advisers LLC bought a new stake in Clovis Oncology (NASDAQ:CLVS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 62,509 shares of the biopharmaceutical company’s stock, valued at approximately $930,000. Virtus ETF Advisers LLC owned 0.11% of Clovis Oncology as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Trust Advisors LP purchased a new stake in Clovis Oncology in the second quarter valued at approximately $723,000. Gabelli Funds LLC raised its position in Clovis Oncology by 143.6% in the second quarter. Gabelli Funds LLC now owns 108,900 shares of the biopharmaceutical company’s stock valued at $1,619,000 after purchasing an additional 64,200 shares during the period. Bourgeon Capital Management LLC purchased a new stake in Clovis Oncology in the second quarter valued at approximately $186,000. Sector Gamma AS raised its position in Clovis Oncology by 13.6% in the second quarter. Sector Gamma AS now owns 431,425 shares of the biopharmaceutical company’s stock valued at $6,415,000 after purchasing an additional 51,648 shares during the period. Finally, Pictet Asset Management Ltd. raised its position in Clovis Oncology by 49.5% in the first quarter. Pictet Asset Management Ltd. now owns 145,800 shares of the biopharmaceutical company’s stock valued at $3,619,000 after purchasing an additional 48,300 shares during the period. 91.69% of the stock is currently owned by institutional investors.
In related news, Director Thorlef Spickschen acquired 9,200 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $5.46 per share, for a total transaction of $50,232.00. Following the completion of the purchase, the director now directly owns 49,576 shares of the company’s stock, valued at approximately $270,684.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lindsey Rolfe sold 1,728 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $14.70, for a total transaction of $25,401.60. Following the completion of the transaction, the insider now owns 23,319 shares of the company’s stock, valued at approximately $342,789.30. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 107,800 shares of company stock valued at $612,094 and sold 2,597 shares valued at $30,139. Corporate insiders own 8.30% of the company’s stock.
A number of research firms have recently weighed in on CLVS. Bank of America lowered Clovis Oncology from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $13.00 to $7.00 in a research report on Tuesday, August 13th. Barclays set a $36.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, August 2nd. G.Research reaffirmed a “buy” rating on shares of Clovis Oncology in a research report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Clovis Oncology in a research report on Wednesday, July 3rd. Finally, Piper Jaffray Companies reaffirmed a “neutral” rating on shares of Clovis Oncology in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of “Hold” and a consensus target price of $25.09.
NASDAQ CLVS traded down $0.13 during trading hours on Friday, hitting $5.58. The company had a trading volume of 118,292 shares, compared to its average volume of 3,114,332. The company has a debt-to-equity ratio of 8.04, a quick ratio of 3.32 and a current ratio of 3.57. Clovis Oncology has a 1-year low of $4.98 and a 1-year high of $34.63. The company has a market cap of $315.39 million, a PE ratio of -0.80 and a beta of 1.91. The business has a 50 day moving average of $6.97 and a 200-day moving average of $16.33.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($0.57). Clovis Oncology had a negative net margin of 332.18% and a negative return on equity of 372.68%. The company had revenue of $32.98 million during the quarter, compared to analyst estimates of $34.92 million. During the same quarter in the prior year, the company earned ($1.94) EPS. The business’s revenue was up 38.8% on a year-over-year basis. Sell-side analysts expect that Clovis Oncology will post -7.51 earnings per share for the current fiscal year.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Story: Is a Roth IRA right for you?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.